{"id":"W4392631648","doi":"10.1136/ijgc-2024-esgo.1115","title":"#88 Lenvatinib plus pembrolizumab versus chemotherapy as first-line therapy for advanced or recurrent endometrial cancer: primary results of the phase 3 ENGOT-en9/LEAP-001 study","year":2024,"lang":"en","type":"article","venue":"International Journal of Gynecological Cancer","topic":"Endometrial and Cervical Cancer Treatments","field":"Medicine","cited_by":10,"is_retracted":false,"has_abstract":false,"ca_institutions":"McGill University Health Centre","funders":"","keywords":"Lenvatinib; Pembrolizumab; Oncology; Endometrial cancer; Medicine; Internal medicine; Chemotherapy; Cancer; Immunotherapy","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001821448,0.001006519,0.002112339,0.0003074947,0.0003102172,0.001012123,0.0006784229,0.001048825,0.006159652],"category_scores_gemma":[0.001423808,0.0005131982,0.003051761,0.0003090081,0.0004954634,0.000961767,0.000334168,0.003434033,0.001423679],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000904526,"about_ca_system_score_gemma":0.0009022119,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001566118,"about_ca_topic_score_gemma":0.005497155,"domain_scores_codex":[0.999459,0.0003301385,0.00002672542,0.00006922969,0.00003982729,0.00007515041],"domain_scores_gemma":[0.9992848,0.0002351148,0.000151096,0.00005455393,0.0000478615,0.0002266152],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.9168713,0.006092216,0.003145121,0.001186711,0.006179727,0.00006869602,0.00006391264,0.001214845,0.00358029,0.0002321852,0.007182962,0.05418205],"study_design_scores_gemma":[0.8312539,0.1356383,0.0184389,0.0001601941,0.0055727,0.0001224728,0.00007598346,0.001360034,0.0009169981,0.0004419117,0.005981595,0.00003706396],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9630207,0.01465273,0.0007958623,0.002471196,0.0009867271,0.001709438,0.007809798,0.0001533804,0.008400148],"genre_scores_gemma":[0.967849,0.006597412,0.001956783,0.003929189,0.0006844921,0.00148038,0.006269526,0.00008530279,0.01114782],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006159652,"threshold_uncertainty_score":0.0206061,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.08773621335716103,"score_gpt":0.4336017973253529,"score_spread":0.3458655839681918,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}